Logo
Login
$ANNX
$3.76 +$0.06 (1.62%) Close

Company Executives

$ANNX Management Team

Mr. Thomas Wiggans

Independent Chairman of the Board

Age 73
Compensation $323.5K USD
Sex Male

Mr. Douglas Love

President

Chief Executive Officer

Director

Age 57
Compensation $3.673M USD
Sex Male

Dr. Jamie Dananberg

Executive Vice President

Chief Medical Officer

Age 67
Compensation $1.564M USD
Sex Male

Mr. Michael Overdorf

Executive Vice President

Chief Business Officer

Age 55
Compensation $1.397M USD
Sex Male

Dr. Ted Yednock

Executive Vice President

Chief Innovation Officer

Age 67
Compensation $1.564M USD
Sex Male

Ms. Jennifer Lew

Chief Financial Officer

Executive Vice President

Age 52
Compensation $1.440M USD
Sex Female

Dr. Dean Artis

Executive Vice President

Chief Scientific Officer

Age 65
Compensation -
Sex Male

Board of Directors

From the proxy statement filed Apr 27, 2026
Directors
8
serving now
Independent
0 of 1
stated in the proxy; 7 not stated
Average tenure
6.4 years
from year joined
CEO also chairs the board
No
Thomas G. Wiggans
Director Age On board Independent Committees Other public boards 2025 pay Source
Bettina M. Cockroft
59 2022
4 years
 Not stated
Audit Committee
CNS Pharmaceuticals, Inc. $162,215
Douglas Love
CEO
 58 2014
12 years
 Not independent None stated None stated Paid as CEO
Thomas G. Wiggans Leaving at the meeting
Board chair
 Not stated Not stated Not stated None stated None stated $192,215
William H. Carson, M.D.
67 2021
5 years
 Not stated None stated None stated $164,215
William (BJ) Jones, Jr.
62 2025
1 year
 Not stated None stated Apogee Therapeutics, Inc. $475,989
Muneer A. Satter
65 2014
12 years
 Not stated
Audit Committee
None stated $166,215
Jung E. Choi
56 2020
6 years
 Not stated None stated None stated $164,215
William D. Waddill
69 2021
5 years
 Not stated
Audit Committee · Chair
Arrowhead Pharmaceuticals, Inc. $171,215

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 27, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans